Ethambutol
CAS No. : 74-55-5
Price and Availability of
CAS No. : 74-55-5
| Size | Price | Stock |
|---|---|---|
| 5mg | $40 | In-stock |
| 10mg | $68 | In-stock |
| 25mg | $136 | In-stock |
| 50mg | $225 | In-stock |
| 100mg | $380 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-B0535 |
| M.Wt: | 204.31 |
| Formula: | C10H24N2O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Introduction of
74-55-5
:
Ethambutol is an antimycobacterial compound that prevents cell wall formation by inhibiting arabinosyltransferase activity. Ethambutol can be used to establish animal models of hyperuricemia and optic neuropathy. In Vivo:
Ethambutol can be used in animal modeling to build a model of hyperuricemia.
1. Induction of Hyperuricaemic Disease[4][5]
Background
Elevated uric acid levels can lead to crystal deposition and may cause gout, urolithiasis, and urate nephropathy. Ethambutol can cause increased uric acid levels by reducing renal uric acid clearance, ultimately leading to hyperuricemia
Specific Modeling Methods
Rat[4]: Male • Wistar rats • SPF • 200-220 g
Administration: 250 mg/kg • intragastric administration • once daily for 23 days
Administration: 250 mg/kg • intragastric administration • once daily for 23 days
Note
(1) Ethambutol-induced hyperuricemia model should be combined with adenine (HY-B0152) (100 mg/kg; gavage) to achieve better model construction effect[4].
(2) Some compounds can synergistically promote uric acid production, such as: Ethanol and Vitamin B12 (HY-B0315)[5].
(3) Ethambutol-induced hyperuricemia model can be controlled by xanthine oxidase inhibitors.
(2) Some compounds can synergistically promote uric acid production, such as: Ethanol and Vitamin B12 (HY-B0315)[5].
(3) Ethambutol-induced hyperuricemia model can be controlled by xanthine oxidase inhibitors.
Modeling Indicators
Molecular changes: URAT1 level in kidney homogenate ↑, OAT1 level ↓.
Physiological changes: Serum uric acid level ↑; sparse cells, tissue cell number ↑, lymphocyte number ↓.
Pathological changes: Pathological damage and inflammatory response in the thymus and spleen; thymus atrophy, cortical medullary fusion; splenic sinus congestion, with iron-yellow deposits.
Opposite Product(s): Xanthine Oxidase Inhibitors
2. Induction of Optic Neuropathy[6]
Background
Ethambutol treatment can cause binocular toxicity at certain doses and durations. There is currently no clear treatment to prevent damage to retinal neuronal cells in cases of Ethhambutol-induced optic neuropathy (EON).
Specific Modeling Methods
Rat: Wistar rats
Administration: 35 mg/kg/day (Ethambutol) • po • 30 days
Administration: 35 mg/kg/day (Ethambutol) • po • 30 days
Modeling Indicators
Molecular changes: Bcl-2, Caspase-3 expression levels ↑.
Pathological indicators: Ganglion cell damage, increased density of retinal ganglion cells (RGCs); thickening of the RGC cell layer due to vacuoles formed in the ganglion cell cytoplasm.
Opposite Product(s): Citicoline (HY-B0739)
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Ethambutol
- Cat. No.:
- HY-B0535
- Quantity:
Your information is safe with us.